# EDGAR Filing Document

**Accession Number:** 0001421642
**File Stem:** 0001171843-26-004176
**Filing Date:** 2026-6
**Character Count:** 4631
**Document Hash:** f2bef46a3d6a217fb8985ae75f54a859
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-004176.hdr.sgml**: 20260617

**ACCESSION NUMBER**: 0001171843-26-004176

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260617

**FILED AS OF DATE**: 20260617

**DATE AS OF CHANGE**: 20260617

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Satellos Bioscience Inc.
- **CENTRAL INDEX KEY:** 0001421642
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43107
- **FILM NUMBER:** 261099319

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 15 ALLSTATE PARKWAY
- **STREET 2:** SUITE 600
- **CITY:** MARKHAM
- **PROVINCE COUNTRY:** A6
- **ZIP:** L3R 5B4
- **BUSINESS PHONE:** 647-660-1780

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 15 ALLSTATE PARKWAY
- **STREET 2:** SUITE 600
- **CITY:** MARKHAM
- **PROVINCE COUNTRY:** A6
- **ZIP:** L3R 5B4

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ICO THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20071218

**<br> UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER<br> PURSUANT TO RULE 13a-16 OR 15d-16<br> OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of June 2026**

**(Commission File No. 001-43107)**

**SATELLOS BIOSCIENCE INC.**

**(Translation of registrant's name into English)**

**15 Allstate Parkway, Suite 600**

**Markham, Ontario, Canada, L3R 5B4**

**(Address of registrant's principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☐ Form 40-F ☒

**DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K**

---

| | |
|:---|:---|
| **<u>Exhibit</u>** | **<u>Description</u>** |
| [99.1](exh_991.htm) | [Report of Voting Results](exh_991.htm) |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Satellos Bioscience Inc.** | **Satellos Bioscience Inc.** |
| By: | /s/ Elizabeth Williams, CPA, CA |
| Name: | Elizabeth Williams, CPA, CA |
| Title: | Chief Financial Officer |

---

Date: June 17, 2026

## Exhibit 99.1

**Exhibit 99.1**

![](logo.jpg)

**Report of Voting Results**

**Satellos Bioscience Inc.**

In accordance with Section 11.3 of National Instrument 51-102, the following briefly describes the matters voted upon and the outcome of the votes at the annual meeting of shareholders of Satellos Bioscience Inc. (the "Company") held virtually on June 17, 2026 (the "**Meeting**"). Full details of the matters are set out in the Company's management information circular dated May 14, 2026, which is available on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov).

&nbsp;&nbsp;&nbsp;&nbsp;1. By resolution passed by way of ballot, each of the nominees for election as directors was elected to hold
office until the next annual meeting of shareholders or until such director resigns or a successor is elected or appointed. Votes at the
Meeting were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Director** | **Votes For** | **% For** | **Votes Against** | **% Against** |
| Frank Gleeson | 9473905 | 99.94 | 5348 | 0.06 |
| Franklin M. Berger | 9478576 | 99.99 | 677 | 0.01 |
| Brian Bloom | 9476755 | 99.97 | 2498 | 0.03 |
| Stephanie Brown | 8741404 | 92.22 | 737849 | 7.78 |
| Selwyn Ho | 9473538 | 99.94 | 5715 | 0.06 |
| Iris Loew-Friedrich | 7939800 | 83.76 | 1539453 | 16.24 |
| Geoff Mackay | 9449959 | 99.69 | 29294 | 0.31 |
| Adam Mostafa | 9450311 | 99.69 | 28942 | 0.31 |
| Mark Nawacki | 9477041 | 99.98 | 2212 | 0.02 |

---

&nbsp;&nbsp;&nbsp;&nbsp;2. By resolution passed by way of ballot, PricewaterhouseCoopers LLP was appointed as auditor of the Company
to hold office until the next annual meeting or until its successor is appointed, and the directors were authorized to fix its remuneration.
98.69% of the votes represented in person or by proxy at the Meeting were in favour of the appointment and 1.31% were withheld from voting.

In total, approximately 55.33% of the issued and outstanding shares were represented in person or by proxy at the Meeting.

Yours very truly,

/s/ Liz Williams

Chief Financial Officer and Corporate Secretary